Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 19/20 | 0.50 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.42 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.42 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16781781 | 1.00 | SLC5A2 (0.50) | SLC5A2SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL18870681 | 1.00 | SLC5A2 (0.50) | SLC5A2SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL5484694 | 1.00 | SLC5A2 (0.50) | SLC5A2SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL16631540 | 1.00 | SLC5A2 (0.50) | SLC5A2SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL17082382 | 1.00 | SLC5A2 (0.50) | SLC5A2SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL16631946 | 1.00 | SLC5A2 (0.50) | SLC5A2SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL16631566 | 0.87 | CDA (0.40) | SLC5A2SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL18079914 | 0.84 | SLC5A2 (0.44) | SLC5A2SLC5A1 | |
| SCHEMBL18870679 | 0.81 | SLC5A2 (0.35) | SLC5A2 | |
| SCHEMBL17378615 | 0.81 | SLC5A2 (0.35) | SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3903392-B2 | — | — | 2007-04-11 | — | — | JP | claimed |
| US-6248878-B1 | INCLUDING BASES 2-FLUOROPYRIDINE-3-YL, PYRIDINE-2-ONE-3-YL, PYRIDIN-2-(4-NITROPHENYLETHYL)-ONE-3-YL, 2-BROMOPYRIDINE-5-YL , PYRIDIN-2-ONE-5-YL, 2-AMINOPYRIDINE-5-YL, PYRIDIN-2-(4-NITROPHENYLETHYL)-ONE-5-YL; ANTISENSE/ANTICANCER AGENTS | RIBOZYME PHARMACEUTICALS, INC. | 2001-06-19 | — | — | US | claimed |
| JP-2001507688-A | — | — | 2001-06-12 | — | — | JP | claimed |
| EP-0948511-A2 | CHEMICAL SYNTHESIS OF NUCLEOSIDES ANALOGS AND THEIR INCORPORATION INTO POLYNUCLEOTIDES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-10-13 | — | — | EP | claimed |
| WO-1998028317-A2 | SYNTHESIS OF NUCLEOSIDES AND POLYNUCLEOTIDES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-07-02 | — | — | WO | claimed |
| US-20190255194-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX INC (US) | 2019-08-22 | — | — | US | disclosed |
| US-10286086-B2 | Alternative nucleic acid molecules and uses thereof | MODERNATX, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| EP-3157572-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| EP-3157573-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| EP-2918275-A1 | Alternative nucleic acid molecules and uses thereof | Roy, Atanu (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20150167017-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2015-06-18 | — | — | US | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
| EP-0948511-B1 | CHEMICAL SYNTHESIS OF NUCLEOSIDES ANALOGS AND THEIR INCORPORATION INTO POLYNUCLEOTIDES | SIRNA THERAPEUTICS INC (US) | 2006-10-18 | — | — | EP | disclosed |
| US-6248878-B1 | INCLUDING BASES 2-FLUOROPYRIDINE-3-YL, PYRIDINE-2-ONE-3-YL, PYRIDIN-2-(4-NITROPHENYLETHYL)-ONE-3-YL, 2-BROMOPYRIDINE-5-YL , PYRIDIN-2-ONE-5-YL, 2-AMINOPYRIDINE-5-YL, PYRIDIN-2-(4-NITROPHENYLETHYL)-ONE-5-YL; ANTISENSE/ANTICANCER AGENTS | RIBOZYME PHARMACEUTICALS, INC. | 2001-06-19 | — | — | US | disclosed |
| US-6248878-B1 | INCLUDING BASES 2-FLUOROPYRIDINE-3-YL, PYRIDINE-2-ONE-3-YL, PYRIDIN-2-(4-NITROPHENYLETHYL)-ONE-3-YL, 2-BROMOPYRIDINE-5-YL , PYRIDIN-2-ONE-5-YL, 2-AMINOPYRIDINE-5-YL, PYRIDIN-2-(4-NITROPHENYLETHYL)-ONE-5-YL; ANTISENSE/ANTICANCER AGENTS | RIBOZYME PHARMACEUTICALS, INC. | 2001-06-19 | — | — | US | disclosed |
| EP-0948511-A2 | CHEMICAL SYNTHESIS OF NUCLEOSIDES ANALOGS AND THEIR INCORPORATION INTO POLYNUCLEOTIDES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998028317-A2 | SYNTHESIS OF NUCLEOSIDES AND POLYNUCLEOTIDES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | SLC5A2 2966/4885SLC28A1 317/4885SLC28A2 259/4885 |
| US-20190255194-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | SLC5A2 2966/4885SLC28A1 317/4885SLC28A2 259/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | SLC5A2 2966/4885SLC28A1 317/4885SLC28A2 259/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | SLC5A2 2966/4885SLC28A1 317/4885SLC28A2 259/4885 |
| US-10286086-B2 | Alternative nucleic acid molecules and uses thereof | NSUN2, RNGTT, NSUN3 | SLC5A2 2966/4885SLC28A1 317/4885SLC28A2 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.